Biomarkers Market Outlook

The global sales of Biomarkers in 2021 was held at US$ 59.1 Bn. With 15.3%, the projected market growth during 2022 – 2032 is expected to be significantly higher than the historical growth. Safety Biomarkers are expected to be the highest revenue generating biomarker type, with a projected growth of 15.9% during 2022 – 2032.

Request Sample- https://www.factmr.com/connectus/sample?flag=S&rep_id=7181

Key Points Covered in Biomarkers Industry Survey:

• Market Estimates and Forecasts (2017-2032)
• Key Drivers and Restraints Shaping Market Growth
• Segment-wise, Country-wise, and Region-wise Analysis
• Competition Mapping and Benchmarking
• Market Share Analysis
• COVID-19 Impact on Biomarkers and How to Navigate
• Recommendation on Key Winning Strategies

Market Segments Covered in Biomarkers Industry Analysis

• By Disease Type :

  • Cardiovascular Diseases
  • Cancer
  • Neurological Diseases
  • Immunological Diseases
  • Other Disease Types

• By Type :

  • Safety
  • Efficacy
  • Validation

• By Application :

  • Diagnostics
  • Drug Discovery & Development
  • Personalized Medicines
  • Other Applications

Competitive Analysis

The key players such as F. Hoffmann-La Roche Ltd.; Abbott Laboratories; Epigenetics AG; Johnson & Johnson Services, Inc.; Thermo Fisher Scientific, Inc. adopt several organic and inorganic strategies to enhance their revenue and market standings.

Some of the recent developments of key Biomarkers providers are as follows:

• In May, 2021, Cerascreen KRAS RGQ PCR Kit, the first FDA-approved diagnostic tissue specimen to identify KRAS G12C mutations in QIAGEN NV NSCLC tumors and expand precision medical options for lung cancer, was launched.
• In April, 2021, F. Hoffmann La Roche Ltd. launched two cardiac biomarker tests, the Sensitive Cardiac Troponin T (cTnThs) and the N-Terminal Pro Brain Sodium Diuretic Peptide Test (NTproBNP). These gold standard biomarkers support the management of cardiovascular disease and may help physicians diagnose heart attacks and better manage heart failure.
• In July 2020, Thermo Fisher Scientific has signed an agreement with Chugai to expand the use of oncomin Dx targeted tests in patients with non-small cell lung cancer (NSCLC) and accelerate local biomarker tests.
• In January 2020, in partnership with the Institute for Microbial Technology (CSIRIMTECH), Merck KGaA opened a research institute in Chandigarh, India, with a focus on genome editing, biomarker detection, and life sciences. The facility is equipped with cutting-edge technology needed for on-site students.